Global Charcot–Marie–Tooth Disease Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)

Global Charcot–Marie–Tooth Disease Drug Pipeline Analysis is projected to register a strong CAGR during the forecast period (2026-2035).

The Charcot–Marie–Tooth disease pipeline reflects a broader transformation occurring within rare genetic neurology because advances in molecular medicine are enabling more targeted therapeutic development. Greater understanding of disease mechanisms is increasing interest in mutation-specific intervention strategies. Clinical development remains constrained by limited patient populations and substantial genetic diversity. Developers are investing in precision medicine platforms and genetic diagnostic integration to improve program feasibility. This effort strengthens the relationship between epidemiology, diagnosis, and therapeutic innovation.

Pipeline activity increasingly depends on accurate genetic classification because treatment eligibility and clinical trial participation often require molecular confirmation. Wider adoption of genetic testing is increasing identification of patients with specific disease-causing mutations. Access disparities continue limiting diagnosis and enrollment opportunities in some regions. Healthcare providers and research organizations are expanding testing infrastructure and patient registries to improve identification. This development enhances the quality of patient selection and clinical research.

Rare disease innovation remains strategically important because disease-modifying therapies are still limited despite substantial unmet need. Growing recognition of progressive disability associated with CMT is increasing demand for interventions capable of altering disease progression. Scientific uncertainty continues influencing development timelines and investment decisions. Sponsors are pursuing diversified approaches that include RNA technologies, gene therapies, neuroprotective mechanisms, and regenerative strategies. This trend supports a more robust and diversified development landscape.

Market Dynamics

Market Drivers

• Expansion of Precision Medicine in Neuromuscular Disorders: Precision medicine is becoming increasingly important because inherited mutations directly influence disease development and progression. Genetic testing adoption is increasing identification of patient subgroups suitable for targeted interventions. Clinical complexity continues creating challenges for broad treatment approaches. Developers are aligning therapeutic strategies with specific molecular mechanisms to improve effectiveness. This evolution strengthens demand for mutation-focused programs.

• Growth of Genetic Testing and Patient Identification: Genetic confirmation plays a central role in modern CMT management because molecular diagnosis improves subtype classification and trial eligibility. Testing utilization is increasing as awareness grows among neurologists and rare disease specialists. Access disparities continue affecting diagnosis rates in some healthcare systems. Healthcare organizations are expanding testing infrastructure and counseling services to improve accessibility. This effort supports growth in genetically characterized patient populations.

• Increasing Investment in Rare Neurological Diseases: Rare disease research attracts increasing attention because significant unmet clinical need persists despite advances in supportive care. Greater disease visibility is increasing demand for therapeutic innovation and long-term management solutions. Scientific uncertainty continues influencing development risk. Investors and developers are supporting diversified research programs to improve future treatment options. This trend strengthens pipeline expansion.

• Expansion of Patient Registries and Natural History Research: Clinical development depends on understanding disease progression because endpoint selection and patient stratification require reliable longitudinal data. Registry participation is increasing as researchers seek larger datasets and more accurate patient characterization. Geographic variability continues affecting data consistency. International collaborations are strengthening data harmonization initiatives to improve research quality. This process supports more efficient development planning.

Market Restraints

• Genetic heterogeneity limits broad therapeutic applicability because numerous mutations contribute to disease development.

• Small patient populations create recruitment challenges for clinical trials.

• Long development timelines and limited natural history data continue increasing scientific and regulatory uncertainty.

Market Opportunities

• Development of Mutation-Specific Therapies: Targeted therapies are becoming increasingly feasible because advances in molecular diagnostics improve understanding of disease-causing mutations. Identification of genetically defined patient populations is increasing demand for precision interventions. Recruitment challenges remain because some mutations affect limited populations. Developers are strengthening global patient identification efforts to improve feasibility. This trend supports expansion of personalized medicine approaches.

• Growth of RNA-Based Therapeutic Platforms: RNA technologies are attracting increasing interest because they offer potential methods for modifying disease-associated gene expression. Expanded molecular characterization is increasing identification of patients who may benefit from targeted approaches. Scientific complexity continues requiring extensive validation. Research programs are strengthening translational development strategies to improve clinical applicability. This effort supports continued innovation.

• Expansion of Gene Therapy Development: Gene therapy programs are becoming increasingly relevant because inherited genetic abnormalities drive many forms of CMT. Earlier diagnosis is increasing opportunities to identify eligible patient populations. Technical and regulatory challenges continue influencing development timelines. Sponsors are investing in platform optimization and clinical research infrastructure to address these barriers. This development strengthens long-term therapeutic potential.

• Biomarker and Digital Endpoint Innovation: Clinical development increasingly depends on objective disease measurement because traditional outcome assessments may not fully capture progression patterns. Biomarker research and digital monitoring technologies are expanding to improve evaluation accuracy. Validation requirements continue creating implementation challenges. Researchers are strengthening observational studies to support endpoint development. This effort enhances future clinical trial efficiency.

Disease & Epidemiology Analysis

Charcot–Marie–Tooth disease comprises a heterogeneous group of inherited peripheral neuropathies characterized by progressive motor and sensory dysfunction. Improved genetic understanding is increasing recognition of disease diversity because numerous mutations contribute to distinct clinical phenotypes. Earlier diagnosis is expanding identification of affected individuals who previously remained unclassified. Diagnostic variability continues influencing epidemiological consistency across regions. Healthcare providers are integrating molecular diagnostics more frequently to improve classification. This approach strengthens disease characterization and patient stratification.

The diagnosed population is increasing because awareness of inherited neuropathies continues improving among neurologists and neuromuscular specialists. Expanded testing utilization is improving identification of mutation-specific patient cohorts relevant to clinical development. Access disparities continue affecting diagnosis rates in some healthcare systems. Patient advocacy organizations and healthcare providers are promoting earlier evaluation and referral practices to address these challenges. This effort supports growth in genetically confirmed populations.

Treatment demand remains largely associated with supportive management because disease-modifying therapies remain under investigation. Progressive weakness, sensory impairment, gait abnormalities, and functional decline continue creating long-term healthcare needs. Multidisciplinary care models are expanding because coordinated neurological, orthopedic, rehabilitative, and genetic services improve patient support. This trend increases engagement between patients and healthcare systems.

Treatment Guidelines Landscape

Market Segmentation

By Development Phase

Preclinical development represents a significant portion of the Charcot–Marie–Tooth pipeline because advances in genetic medicine are enabling exploration of novel therapeutic approaches. Research activity is increasing around mutation-specific interventions as understanding of disease biology improves. Scientific complexity remains a major constraint because multiple genetic mechanisms contribute to disease heterogeneity. Developers are expanding translational research programs to validate targets and optimize delivery platforms. This trend supports continued growth in early-stage innovation.

By Mechanism of Action

Gene therapy approaches are receiving increasing attention because inherited genetic abnormalities directly contribute to disease development. Improved molecular diagnostics are expanding identification of patients who may benefit from targeted intervention. Technical challenges continue affecting delivery and long-term efficacy assessment. Developers are investing in platform optimization and translational research to address these barriers. This trend strengthens the role of gene-targeted innovation.

By Modality

Small molecules remain an important modality because established development pathways support efficient clinical translation. Research activity is increasing around compounds targeting disease biology and functional impairment. Demonstrating meaningful disease modification remains challenging. Developers are optimizing target selection and patient stratification strategies to improve outcomes. This effort supports continued modality relevance.

Regional Analysis

North America

North America maintains one of the largest diagnosed CMT populations because advanced neurological services and genetic testing infrastructure support comprehensive disease identification. Earlier diagnosis is increasing demand for specialist neuromuscular care, rehabilitation services, and long-term monitoring. Geographic disparities continue affecting access among rural and underserved populations. Healthcare providers are expanding telemedicine and specialist outreach initiatives to improve accessibility. This effort strengthens patient identification and management across the region.

The United States contributes substantially to regional disease recognition because patient advocacy organizations and specialist centers actively support awareness initiatives. Improved recognition of inherited neuropathies is increasing referrals for genetic testing and clinical evaluation. Healthcare systems are strengthening multidisciplinary care pathways to support growing patient populations. This response improves continuity of care and long-term disease management.

Canada supports continued growth in diagnosed populations because publicly funded healthcare systems facilitate access to specialist neurological assessment. Geographic distribution creates challenges for some patients living far from major academic centers. Telehealth adoption is improving access to expertise and facilitating earlier diagnosis. This effort strengthens patient engagement across the care continuum.

Europe

Europe remains a major contributor to global epidemiological knowledge because collaborative neuromuscular networks and patient registries support disease surveillance. Improved awareness is increasing diagnosis rates as healthcare providers become more familiar with inherited neuropathies. Differences in healthcare infrastructure create variability in access to genetic testing and specialist care. Research organizations are strengthening international collaboration to improve consistency. This effort enhances regional epidemiological understanding.

Countries including Germany, the United Kingdom, France, Italy, and Spain continue contributing substantial patient data through registry participation and natural history studies. Earlier diagnosis is increasing demand for rehabilitation, orthopedic support, and long-term neurological care. Workforce limitations continue affecting specialist access in some healthcare systems. Providers are strengthening multidisciplinary management frameworks to improve service delivery. This development supports sustained patient engagement.

European research programs continue improving understanding of genotype-phenotype relationships because larger patient cohorts are participating in structured observational studies. Registry expansion increases the quality of epidemiological evidence available for healthcare planning. This trend supports more accurate population forecasting and healthcare resource allocation.

Asia Pacific

Asia Pacific is experiencing increasing recognition of CMT because healthcare infrastructure improvements are expanding access to neurological assessment and molecular diagnostics. Historically lower diagnosis rates limited understanding of disease burden, yet awareness initiatives are improving identification among clinicians. Specialist workforce shortages continue affecting access in several countries. Governments and healthcare organizations are investing in neuromuscular disease education and diagnostic capabilities to address these gaps. This effort supports growth in diagnosed populations.

Japan remains one of the most organized regional markets for inherited neurological disease management because specialist neuromuscular services are well established. Earlier recognition of motor and sensory symptoms is increasing demand for comprehensive diagnostic evaluation. Healthcare providers are strengthening integrated care pathways to improve patient support. This response supports long-term disease management.

China, South Korea, Australia, and India are increasing investment in rare disease awareness because improved diagnosis expands understanding of national disease burden. Geographic disparities continue affecting access to specialized services. Healthcare systems are strengthening referral networks and genetic testing infrastructure to address these limitations. This trend supports continued growth in recognized patient populations.

Rest of the World

The Rest of the World region continues facing diagnostic challenges because specialist neuromuscular services and genetic testing infrastructure remain limited in many countries. Improved awareness is increasing diagnosis rates, which expands demand for neurological assessment, rehabilitation, and supportive care services. Healthcare infrastructure limitations constrain patient identification and management. Clinical organizations are supporting education and capacity-building initiatives to improve recognition. This effort enhances visibility of disease burden.

Latin American healthcare systems are increasing focus on rare inherited neurological disorders because patient advocacy organizations are highlighting unmet diagnostic needs. Improved access to specialist evaluation is expanding diagnosis rates. Economic constraints continue affecting comprehensive service delivery. Healthcare stakeholders are strengthening referral pathways to improve patient access. This development supports gradual growth in diagnosed populations.

Middle Eastern and African healthcare systems are developing greater awareness of inherited neuropathies because healthcare modernization efforts are expanding diagnostic capabilities. Limited epidemiological data continue constraining understanding of prevalence and incidence. International collaborations are improving disease surveillance and professional education. This process supports future patient identification and management.

Regulatory Landscape

Rare disease regulatory frameworks increasingly influence CMT development because many therapeutic candidates target genetically defined patient populations. Regulatory agencies are encouraging innovative development approaches that address substantial unmet need. Evidence requirements remain rigorous because demonstration of clinical benefit remains essential for approval. Developers are strengthening interactions with regulatory authorities to align study design with expectations. This process improves development efficiency.

Genetic testing regulations are becoming increasingly important because molecular confirmation plays a central role in patient identification and trial eligibility. Expanded testing utilization is increasing demand for guidance regarding data management, counseling, and informed consent. Regulatory authorities are refining policies to support responsible implementation of genomic medicine. This effort improves consistency across healthcare systems.

Clinical trial regulations continue evolving because precision medicine programs often involve small and geographically dispersed patient populations. Adaptive study designs and innovative endpoints are receiving greater attention as stakeholders seek more efficient development pathways. Sponsors are incorporating natural history data and biomarker strategies into regulatory planning to strengthen evidence generation. This development supports future advancement of targeted therapies.

Pipeline Analysis

Charcot–Marie–Tooth disease pipeline activity is increasingly shifting toward genetically targeted interventions because advances in molecular diagnostics are improving identification of disease-causing mutations. Development programs are focusing on underlying biological mechanisms rather than symptomatic management alone, which increases demand for precise patient stratification and genetic confirmation. Clinical development remains constrained by disease heterogeneity because more than one hundred genetic variants contribute to diverse phenotypes. Sponsors are strengthening precision medicine strategies and expanding use of natural history datasets to improve study design. This evolution supports the transition toward disease-modifying therapeutic development.

RNA-based technologies, gene therapies, and mutation-specific approaches are receiving growing attention because inherited genetic abnormalities directly influence disease progression. Earlier diagnosis is increasing the number of genetically characterized patients available for research participation. Recruitment challenges continue because individual subtypes frequently affect small patient populations that are geographically dispersed. Developers are leveraging international registries, advocacy networks, and specialist neuromuscular centers to improve enrollment efficiency. This effort enhances the feasibility of advanced clinical development programs.

Clinical development increasingly depends on robust natural history data because slowly progressive disease patterns can complicate endpoint evaluation and efficacy assessment. Registry participation is expanding as stakeholders seek more accurate information regarding progression trajectories and functional decline. Variability in disease severity continues affecting interpretation of outcomes. Research organizations are strengthening longitudinal observational studies to improve understanding of disease evolution. This process supports more effective therapeutic evaluation and regulatory planning.

Reimbursement Landscape

The reimbursement environment for Charcot–Marie–Tooth disease currently centers on supportive care because disease-modifying therapies remain limited. Earlier diagnosis is increasing demand for specialist consultations, physiotherapy, occupational therapy, mobility support, and genetic testing. Healthcare systems continue facing resource allocation pressures because disease progression often requires lifelong management. Policymakers are evaluating reimbursement frameworks that improve access while maintaining sustainability. This effort supports long-term patient care.

Genetic testing reimbursement is becoming increasingly important because molecular confirmation influences diagnosis, family counseling, and future therapeutic eligibility. Expanded testing utilization is increasing demand for coverage policies that support earlier identification of disease subtypes. Variability in reimbursement structures continues affecting access across healthcare systems. Authorities are reviewing coverage strategies to reduce barriers and improve consistency. This development expands opportunities for genetically informed care.

Rehabilitation and mobility support services remain major components of healthcare utilization because progressive weakness and sensory impairment affect long-term function. Earlier diagnosis is increasing engagement with multidisciplinary care programs and assistive technologies. Healthcare providers are strengthening integrated care pathways to improve continuity of support. This response enhances patient management throughout disease progression.

Competitive Landscape

Pharnext

Pharnext is strategically distinct because of its historical focus on Charcot–Marie–Tooth Type 1A, one of the most prevalent genetically defined forms of the disease. Growing adoption of genetic testing is increasing identification of PMP22-associated patient populations, which strengthens interest in subtype-specific therapeutic approaches. Earlier diagnosis expands opportunities to evaluate interventions across a broader disease continuum. Clinical investigators are increasingly incorporating molecular confirmation into patient selection strategies to improve study precision. This development enhances the importance of subtype-focused innovation.

The company benefits from increasing recognition that disease heterogeneity requires more targeted management approaches. Diagnostic delays continue affecting timely identification because symptom severity varies substantially among patients. Healthcare providers are strengthening referral pathways and genetic testing utilization to improve earlier diagnosis. This effort expands opportunities for therapeutic development aligned with specific molecular mechanisms.

Pharnext’s competitive position remains closely associated with growing understanding of genetically defined neuropathies. Improved classification increases demand for therapies designed around specific disease biology. This trend reinforces the strategic relevance of subtype-focused development programs.

NMD Pharma

NMD Pharma differentiates itself through its focus on improving neuromuscular function and addressing functional impairment associated with neurological disorders. Growing awareness of mobility limitations and progressive weakness is increasing interest in approaches capable of enhancing neuromuscular performance. Earlier diagnosis expands opportunities for intervention before substantial disability develops. Clinical research increasingly incorporates functional endpoints to evaluate real-world patient benefit. This evolution strengthens the relevance of neuromuscular performance-focused strategies.

The company benefits from increasing emphasis on quality-of-life improvement because long-term disability remains a major burden for affected individuals. Functional variability continues creating challenges for therapeutic evaluation and outcome measurement. Research programs are strengthening patient stratification methodologies to improve assessment consistency. This effort enhances understanding of treatment impact and clinical value.

NMD Pharma’s position is reinforced by growing recognition that supportive functional improvement may remain important even as disease-modifying therapies advance. Expanding diagnosis rates increase demand for interventions that address day-to-day patient needs. This environment supports continued strategic relevance.

DTx Pharma

DTx Pharma is strategically differentiated through its expertise in RNA-based therapeutic technologies. Molecular characterization is increasing demand for approaches capable of targeting disease-associated genetic pathways because inherited mutations drive disease progression. Genetic testing adoption is expanding identification of mutation-specific populations that may benefit from precision medicine approaches. Clinical development programs are refining enrollment strategies around genetically confirmed cohorts to improve therapeutic precision. This trend enhances the importance of RNA-targeted innovation.

The company benefits from increasing understanding that many CMT subtypes require individualized intervention strategies. Earlier diagnosis expands opportunities to identify eligible patients before advanced disease progression occurs. Small patient populations continue creating recruitment challenges for highly targeted programs. Research collaborations are strengthening patient identification and enrollment capabilities to improve feasibility. This effort supports continued advancement of RNA-based therapeutic development.

DTx Pharma’s competitive position is strengthened by broader momentum toward genetic medicine in rare neurological disorders. Improved molecular classification creates opportunities for highly specific therapeutic approaches. This development reinforces the strategic value of RNA-focused platforms.

AAVantgarde Bio

AAVantgarde Bio is strategically distinct because of its focus on gene therapy technologies for rare inherited diseases. Charcot–Marie–Tooth disease increasingly attracts interest from gene therapy developers because many disease forms arise from clearly defined genetic abnormalities. Earlier diagnosis is increasing identification of mutation carriers who may become candidates for future targeted interventions. Clinical investigators are exploring innovative delivery strategies to improve therapeutic effectiveness in peripheral nerve disorders. This development strengthens opportunities for gene-based medicine.

The company’s approach aligns with growing recognition that mutation-specific populations may require highly specialized therapeutic solutions. Expanded genetic testing is increasing understanding of disease distribution and subtype prevalence. Recruitment challenges remain significant because rare mutations often affect limited patient populations. International research collaborations are strengthening enrollment infrastructure and patient identification efforts to address this constraint. This effort supports advancement of gene therapy development.

AAVantgarde Bio’s competitive position benefits from increasing demand for precision medicine within inherited neurological disorders. Improved understanding of disease genetics creates opportunities for therapies designed to address root biological causes. This trend strengthens the company’s long-term relevance within the evolving CMT pipeline landscape.

Ionis Pharmaceuticals

Ionis Pharmaceuticals is strategically distinct because of its extensive expertise in RNA-targeted therapeutic development across rare genetic disorders. Growing adoption of genetic testing is increasing identification of mutation-specific CMT populations, which strengthens demand for therapies designed around underlying molecular mechanisms. Earlier diagnosis expands opportunities to intervene before substantial neurological decline occurs. Clinical development programs are increasingly integrating genetic stratification and biomarker-driven approaches to improve precision. This trend enhances the importance of RNA-based innovation within inherited neuropathies.

The company benefits from increasing recognition that many CMT subtypes require highly individualized therapeutic strategies. Small patient populations continue creating recruitment challenges because individual mutations may affect limited numbers of patients globally. Research organizations are strengthening international collaboration and registry utilization to improve enrollment efficiency. This effort supports advancement of targeted genetic medicine programs.

Ionis’ competitive position is reinforced by continued growth in precision medicine and molecular therapeutics. Improved disease classification creates opportunities for highly focused intervention strategies. This development strengthens the company’s relevance within future CMT treatment innovation.

Wave Life Sciences

Wave Life Sciences differentiates itself through its focus on precision genetic medicines and RNA-based therapeutic technologies. Molecular characterization is increasing demand for mutation-specific treatment approaches because disease biology varies significantly across CMT subtypes. Earlier diagnosis expands identification of genetically confirmed patients who may become eligible for future targeted interventions. Clinical investigators are refining patient selection methodologies to improve therapeutic precision and study efficiency. This trend strengthens the integration of diagnostics and treatment development.

The company benefits from increasing understanding that hereditary neuropathies require personalized therapeutic approaches. Recruitment remains challenging because rare mutations often affect geographically dispersed populations. International collaborations are strengthening patient identification and enrollment efforts to address these limitations. This effort supports advancement of precision therapeutic programs.

Wave’s competitive relevance is strengthened by broader adoption of genomic medicine across rare neurological diseases. Enhanced patient stratification improves opportunities for mutation-focused innovation. This environment supports long-term strategic positioning.

Sarepta Therapeutics

Sarepta Therapeutics is strategically important because of its established expertise in neuromuscular disorders and genetic medicine development. Growing awareness of inherited neurological diseases is increasing demand for organizations capable of supporting complex clinical development programs. Earlier diagnosis expands opportunities for longitudinal monitoring and therapeutic evaluation. Healthcare providers are strengthening referral pathways and genetic testing utilization to improve patient identification. This trend supports the importance of experienced neuromuscular developers.

The company benefits from increasing investment in rare disease innovation because advances in diagnostics are improving visibility of previously underrecognized patient populations. Clinical development increasingly depends on robust epidemiological data and genetically characterized cohorts. Research networks are expanding observational studies and registry initiatives to strengthen understanding of disease progression. This effort improves the foundation for future therapeutic innovation.

Sarepta’s competitive position is reinforced by its capabilities in genetic medicine and neuromuscular disease research. Growing patient population visibility increases the value of organizations capable of navigating complex rare disease pathways. This development supports continued relevance within the CMT ecosystem.

Strategic Insights and Future Market Outlook

The Charcot–Marie–Tooth disease pipeline is evolving because advances in molecular diagnostics are improving understanding of disease biology and enabling more precise therapeutic development. Genetic testing adoption is increasing identification of mutation-specific populations, which strengthens demand for targeted treatment strategies. Clinical development remains constrained by disease heterogeneity because numerous genetic abnormalities contribute to distinct disease manifestations. Sponsors are strengthening precision medicine frameworks to improve patient stratification and treatment alignment. This trend supports continued expansion of genetically informed therapeutic innovation.

Pipeline diversification is increasing because developers are pursuing multiple technological approaches, including RNA therapeutics, gene therapies, neuroprotective interventions, and regenerative strategies. Earlier diagnosis expands opportunities to identify patients before substantial functional decline occurs. Recruitment challenges continue affecting development timelines because many subtypes remain rare. Research organizations are strengthening registry participation, international collaboration, and natural history studies to improve clinical development readiness. This effort enhances future therapeutic feasibility.

Clinical trial design is becoming increasingly sophisticated because disease progression patterns require sensitive and meaningful outcome measures. Biomarker development and digital assessment technologies are receiving greater attention as stakeholders seek improved methods of evaluating treatment impact. Traditional endpoints continue presenting challenges due to variability in disease progression. Developers are incorporating longitudinal observational data into study planning to improve interpretability. This evolution strengthens the quality of evidence generation.

The regulatory environment is increasingly supporting innovation because rare disease frameworks encourage development of therapies addressing substantial unmet need. Molecular diagnostics are becoming more closely integrated with therapeutic development because patient selection often depends on genetic confirmation. Regulatory expectations continue emphasizing robust efficacy and safety evidence. Sponsors are strengthening engagement with regulatory authorities to improve development efficiency. This process supports future advancement of precision medicine programs.

Long-term pipeline success will depend on the interaction between scientific innovation, patient identification, regulatory support, and healthcare infrastructure. Genetic characterization is expanding because broader testing adoption is improving disease classification and registry enrollment. Clinical development programs are increasingly aligning therapeutic strategies with specific biological mechanisms. This trend strengthens the likelihood that future therapies will address disease at its molecular origin rather than focusing exclusively on symptom management.

Future innovation is expected to concentrate on mutation-specific interventions, advanced RNA technologies, gene therapies, and precision neuromuscular medicine. Growing understanding of disease biology is increasing opportunities for targeted therapeutic development. Healthcare systems are expanding genetic testing capabilities and rare disease support infrastructure to accommodate these changes. This environment supports continued growth of the Charcot–Marie–Tooth therapeutic pipeline through 2031.

Market Scope: